Research programme: cancer therapeutics - Verastem

Drug Profile

Research programme: cancer therapeutics - Verastem

Alternative Names: Salinomycin - Verastem; VS-507; VS-5095; VS-6062

Latest Information Update: 25 May 2016

Price : $50

At a glance

  • Originator Broad Institute; Massachusetts Institute of Technology; S*BIO
  • Developer Verastem
  • Class Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; Focal adhesion protein-tyrosine kinase inhibitors; MTORC1 protein inhibitors; MTORC2 protein inhibitors; Stem cell inhibitors; Wnt signalling pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 03 Mar 2016 Verastem has worldwide patent protection for VS 6062 (Verastem form 10-K, March 2016).
  • 11 Sep 2013 Preclinical development is ongoing in the US
  • 09 Nov 2012 Pharmacodynamics data from a preclinical trial in Cancer presented at the 24th EORTC-NCI-AACR Symposium on Molecular Targets in Cancer Therapeutics (EORTC-NCI-AACR-2012)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top